Macrophages but not Astrocytes Harbor HIV DNA in the Brains of HIV-1-Infected Aviremic Individuals on Suppressive Antiretroviral Therapy

Allen Ko 1 · Guobin Kang 2 · Julian B. Hattler 1 · Hadiza I. Galadima 3,4 · Junfeng Zhang 2,5 · Qingsheng Li 2 · Woong-Ki Kim 1

Received: 17 April 2018 / Accepted: 30 August 2018 / Published online: 7 September 2018
© The Author(s) 2018, corrected publication November/2018

Abstract
The question of whether the human brain is an anatomical site of persistent HIV-1 infection during suppressive antiretroviral therapy (ART) is critical, but remains unanswered. The presence of virus in the brains of HIV patients whose viral load is effectively suppressed would demonstrate not only the potential for CNS to act as an anatomical HIV reservoir, but also the urgent need to understand the factors contributing to persistent HIV behind the blood-brain barrier. Here, we investigated for the first time the presence of cells harboring HIV DNA and RNA in the brains from subjects with undetectable plasma viral load and sustained viral suppression, as identified by the National NeuroAIDS Tissue Consortium. Using new, highly sensitive in situ hybridization techniques, RNAscope and DNAscope, in combination with immunohistochemistry, we were able to detect HIV-1 in the brains of all virally suppressed cases and found that brain macrophages and microglia, but not astrocytes, were the cells harboring HIV DNA in the brain. This study demonstrated that HIV reservoirs persist in brain macrophages/microglia during suppressive ART, which cure/treatment strategies will need to focus on targeting.

Keywords Antiretroviral therapy · Brain · HIV-1 · HIV-associated neurocognitive disorders · Macrophage · Reservoir

Introduction
The combination antiretroviral therapy (ART) has converted a life-threatening human immunodeficiency virus (HIV) infection into a chronic disease. Nevertheless, life-long treatment is required for those with this debilitating "incurable" disease. While much effort has been focused on better understanding the nature of HIV cellular latent reservoir in peripheral blood cells and lymphoid tissues, non-lymphoid tissues including brain have not been rigorously investigated. Furthermore, despite the widespread use of ART, HIV-associated neurocognitive disorders (HAND) remain surprisingly common (Masliah et al. 2000; Sacktor et al. 2002; McArthur et al. 2003; Becker et al. 2011; Harezlak et al. 2011). Even in individuals on successful HAART with undetectable plasma viral load, HAND is still observed (Baeuerle et al. 2005; Simioni et al. 2010; Bingham et al. 2011; Cysique and Brew 2011). The basis of HAND in virally suppressed individuals is unclear, and one possibility is that a cryptic HIV replication in the brain may occur during suppressive
antiretroviral therapy (ART); however, it remains to be tested whether the human brain is an anatomical site of persistent HIV-1 infection and/or ongoing low-level replication during suppressive ART. Moreover, the cell types in brain that persistently harbor HIV DNA and RNA in HIV patients on suppressive ART with undetectable viral load in blood and cerebrospinal fluid (CSF) are not established. Studies on HIV reservoirs in the brain have been largely hampered by the scarcity of autopsy brain tissue from HIV-infected individuals who had been on ART and achieved viral suppression for extended periods before their HIV-unrelated deaths. Furthermore, such studies have also been hampered by the lack of sensitive technologies for detecting the presence of low-copy viral RNA (vRNA) and DNA (vDNA) in specific cell types.

The National NeuroAIDS Tissue Consortium (NNTC) identified a limited number of cases on ART with well-documented, sustained control of HIV-1 (“Virally Suppressed Cases”). Exploiting this unique cohort, we used highly specific in situ hybridization (ISH) with single-copy sensitivity (RNAscope and DNAscope) to detect and quantify HIV-1 vRNA and vDNA in the brain and determined the cell types harboring vRNA and vDNA. We were able to detect persistent HIV-1 DNA in the brains of all 16 virally suppressed cases. In addition, we found that macrophages, including CD206+ perivascular macrophages (PVM) and some CD68+ microglia, harbored vDNA. Interestingly, no evidence for infection of astrocytes was indicated by absence of vDNA in astrocytes. Of note, we found, in some individuals (6/16) on suppressive ART with undetectable viral loads in blood and CSF, the presence of isolated focal vRNA in the brain. Together, these findings suggest that macrophages and microglia are the HIV cellular latent reservoir in brain, and that cure/treatment strategies are needed to focus on targeting the macrophage/microglial viral reservoir in the brain.

Materials and Methods

Study Subjects

The cases for this study were selected from over 900 human autopsied brain specimens in the NNTC. The following 4 groups and a total of 29 cases were examined (Table 1):

- **Group 1 (N = 6)** – HIV-1 uninfected subjects with minimal non-diagnostic abnormalities at autopsy (HIV-);
- **Group 2 (N = 7)** – HIV-1-infected subjects with encephalitis (HIVE);
- **Group 3 (N = 8)** – HIV-1-infected, virally suppressed subjects with HAND (HAND);
- **Group 4 (N = 8)** – HIV-1-infected, virally suppressed subjects with no functional impairment (No HAND). The further selection criteria for Groups 3 and 4 were as follows:
  - Group 3: includes only HIVE-negative, suppressed cases with probable/possible mild neurocognitive disorder or HIV-associated dementia at last pre-mortem visit, but excludes hemorrhage dura/leptomeninges and bacterial parenchymal infection at autopsy.
  - Group 4: includes only HIV negative, suppressed cases with normal or asymptomatic neurocognitive impairment neuropsychological diagnosis at last pre-mortem visit, but exclude hemorrhage dura/leptomeninges and bacterial parenchymal infection at autopsy.

There were only 11 cases available for group 3 and 12 available for group 4. The NNTC sites randomly assigned 8 to each group. Groups 1 and 2 were matched as best as possible with respect to age, sex, and race; there was no statistically significant difference in demographic parameters (Supplementary Table 1). Postmortem intervals were all under 48 h. Please visit the NNTC website (https://nntc.org/cohorts/virally-suppressed-cases) for more information. Users can search for a case by using a PRJID in Table 1.

Neuropsychological Assessment

All virally suppressed subjects received a 2-to-3-h battery of neuropsychological (NP) tests. The tests are fully described elsewhere (Fischer-Smith et al. 2001; Woods et al. 2004), and also listed on the NNTC website. The NP battery included tests of premorbid functioning, speed of information processing, attention/working memory, verbal fluency, learning and memory, abstraction/executive functioning, motor skills, and assessments of everyday functioning and mood. Raw test scores were converted to age and demographically corrected T scores, which were then used to compute a deficit score that ranged from 0 (T score > 39, no impairments) to 5 (T score < 20, severe impairment). Average deficit scores are computed to yield an overall level of NP performance [global deficit score (GDS)] (Blackstone et al. 2012). A diagnosis of HAND at the final pre-mortem visits was made by American Academy of Neurology criteria that were modified by the Frascati recommendations (Janssen et al. 1991; Antinori et al. 2007).

HIV vDNA and vRNA Detection Using DNAscope and RNAscope ISH

HIV DNA and RNA in brain tissues were detected in situ using sense and antisense probes from the RNAscope® ISH probe-V-HIV1-clade B (Cat# 416111,
Advanced Cell Diagnostics) and RNAscope® 2.5 HD assay-Red (Advanced Cell Diagnostics) for color development, respectively. The RNAscope® negative control probe-DapB (Cat# 310043, Advanced Cell Diagnostics) was used as negative control. The DNAscope and RNAscope ISH was conducted according to our previously reported protocol (Yuan et al. 2017). The tissue sections, after RNAscope ISH or DNAscope ISH was performed, were digitized with Aperio CS2 Scanscope. For quantititative image analysis of vRNA- or vDNA-positive cells, a positive pixel count algorithm in Aperio’s Spectrum Plus analysis program (version 9.1; Aperio ePathology Solutions) was used as we previously reported (Wang et al. 2014).

Table 1 Patient characteristics

| ProjID | Category | PMI | Age at death | Sex | R | Risk | CD4 | Plasma vl | CSF vl | Brain pathology | Global deficit score |
|--------|----------|-----|--------------|-----|---|------|-----|-----------|--------|------------------|---------------------|
| 01965  | Uninfected | 11  | 63 | F | W | – | – | – | – | – | – | Abn-unspecified | – |
| 02711  | Uninfected | 29.7 | 54 | M | B | – | – | – | – | – | – | normal | – |
| 02105  | Uninfected | 21.27 | 51 | M | H | – | – | – | – | – | – | normal | – |
| 01640  | Uninfected | 19  | 63 | M | H | – | – | – | – | – | – | normal | – |
| 01902  | Uninfected | 18.5 | 21 | M | H | – | – | – | – | – | – | normal | – |
| 01923  | Uninfected | 6.5 | 61 | M | H | – | – | – | – | – | – | Abn-Focal Infarct | – |
| 00039  | HIVE | 8  | 46 | M | W | Hom-sx | 15 | 107,143 | 11,908 | HIVE | 4.5 |
| 00284  | HIVE | 4  | 36 | M | H | Hom-sx | 16 | 195,269 | – | HIVE | – |
| 00488  | HIVE | 5.5 | 42 | M | W | Hom-sx | 99 | 6940 | 750,000 | HIVE, MGNE | – |
| 01555  | HIVE | 48 | 47 | M | W | Hom-sx | 9 | 210,000 | – | HIVE | – |
| 01580  | HIVE | 4  | 50 | M | H | IVDU | 1 | 58,419 | – | HIVE | – |
| 01598  | HIVE | 27 | 45 | F | B | IVDU | 6 | – | – | HIVE | – |
| 02390  | HIVE | 17 | 63 | F | B | Het-sx | 25 | 730,085 | – | HIVE | – |
| 01374  | Virally Supressed with HAND | 22.5 | 54 | M | W | Hom-sx | 491 | 85 | 50 | minimal | 1.79 |
| 02398  | Virally Supressed with HAND | 4.5 | 64 | M | B | Hom-sx | 1043 | 40 | na | Leukoencephalopathy | – |
| 00630  | Virally Supressed with HAND | 18.5 | 61 | M | B | Het-sx, IVDU | 271 | 50 | 50 | Abn-unspecified | 0.57 |
| 00699  | Virally Suppressed with HAND | 46.5 | 59 | M | B | Hom-sx | 491 | 50 | – | Aseptic Leptomeningitis, Focal infarct, Abn-Alzheimer/Focal Infarct | 2.67 |
| 02035  | Virally Suppressed with HAND | 18.23 | 50 | M | H | Hom-sx | 300 | 20 | – | Abn-Alzheimer/Focal Infarct | 2.62 |
| 01986  | Virally Suppressed with HAND | 8.5 | 69 | M | W | Hom-sx | 355 | 20 | 60 | ischemic | 2.62 |
| 00006  | Virally Suppressed with HAND | 11.5 | 62 | F | B | Het-sx | 392 | 50 | 50 | ischemic | 0.15 |
| 00009  | Virally Suppressed with HAND | 11 | 50 | F | W | Het-sx, IVDU | 791 | 50 | 50 | Abn-unspecified | 0.6 |
| 02104  | Virally Suppressed no HAND | 6  | 47 | M | H | Hom-sx | 61 | 48 | – | Abn-Focal Infarct | 0.36 |
| 01495  | Virally Suppressed no HAND | 7  | 39 | M | B | Het-sx | 112 | 40 | – | ischemic | 0.21 |
| 00697  | Virally Suppressed no HAND | 21 | 66 | M | W | Hom-sx | 798 | 50 | – | Abn-Focal Infarct | 1.21 |
| 00522  | Virally Suppressed no HAND | 24 | 66 | M | W | Hom-sx | 465 | 50 | 50 | normal | 0.07 |
| 00658  | Virally Suppressed no HAND | 6  | 52 | M | W | Hom-sx | 78 | 50 | 50 | normal | 0 |
| 00719  | Virally Suppressed no HAND | 20 | 44 | M | B | IVDU | 219 | 50 | 50 | ischemic | 0.86 |
| 01878  | Virally Suppressed no HAND | 8.5 | 63 | M | W | Hom-sx | 133 | 50 | 50 | ischemic | 1.79 |
| 02087  | Virally Suppressed no HAND | 14.5 | 51 | M | W | Hom-sx | 223 | 50 | 139 | Abn-ChronicHTN | 0.77 |
Determining the Cell Types of vRNA+ and vDNA+ Cells Using RNAscope/DNAscope ISH in Combination with Immunohistochemistry

The tissue sections of vRNA- or vDNA-positive tissue sections post ISH were digitized with Aperio CS2 Scanscope, and then the coverslips of these tissue sections were removed by soaking tissue slides in xylene overnight. The tissue sections were rehydrated for immunohistochemistry (IHC) conducted as we reported (Li et al. 2009). Briefly, mouse-anti-human CD68 monoclonal antibody (KP1, 1:200, Leica), mouse-anti-human CD206 monoclonal antibody (SC11, 1:500, Abnova), or mouse-anti-GFAP monoclonal antibody (ASTRO6, 1:100, Thermo Scientific) was used as the primary antibody. Mouse IgG isotype control antibody was used as negative control. EnVision anti-mouse HRP polymer kit (Cat#: K40011–2, Agilent Dako) and substrate diaminobenzidine (DAB) were used to visualize antibody staining signals as brown. After counterstained with hematoxylin, tissue sections were digitized with Aperio CS2 Scanscope and were analyzed using Aperio’s Spectrum Plus analysis program (version 9.1; Aperio ePathology Solutions) to separate into single channels of vRNA, vDNA, or antibody staining signals. The tissue sections on slides after combined DNAscope ISH with IHC were also reviewed with Olympus Cell-Sens software (1.18) after images were captured with DP72 CCD camera at 60×/1.25 Oil Iris using Olympus microscope. To further determine whether astrocytes support HIV productive infection, fluorescent RNAscope ISH was combined with immunofluorescent staining of GFAP. Donkey anti-mouse IgG conjugated with Alexa Fluor 647 (Cat#: A-31571, Thermo Fisher Scientific) was used as a secondary antibody and cell nuclei were counterstained with DAPI. A Nikon A1R-TiE live cell imaging confocal system was used to visualize and capture images of stained samples.

SAMHD1 IHC

IHC for SAMHD1 was done on human brain tissues as we previously reported (Lindgren et al. 2018)

Statistical Analysis

Descriptive statistics of the cohort data were presented as mean (standard deviation) for continuous variables and frequency (percent) for the categorical variables (Supplementary Table 1). Comparisons of the HIV-infected groups (G2, G3, and G4) within and across each of the three brain regions with respect to HIV vDNA were assessed using a two-way ANOVA. Interaction effect between HIV-infected groups and the brain areas was systematically considered and retained based on its significance. Tukey pairwise multiple comparison was used for the post hoc-analysis. Finally, regression and Pearson correlation analyses were used to examine the relationship between HIV vDNA+ cells with GDS and SAMHD1+ cells in specific brain regions. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and assessed with a statistical significance level of alpha = 0.05.

Results

We set out to determine whether brain harbors HIV vDNA or vRNA or both in the HIV-1-infected aviremic individuals who were on suppressive ART, as well as what type of cells harbor vDNA in those subjects. The NNTC identified 44 (now 56) cases of HIV-infected aviremic subjects who were on suppressive ART and donated the tissues including the brain. From this rare resource we obtained 16 such cases with available cognitive characterization to further stratify by HAND status (8 with HAND and 8 with no HAND). In addition, we included HIV-infected viremic individuals with encephalitis (HIVE group; n = 7) and HIV-1 uninfected individuals as controls (Table 1).

We studied 3 brain regions, frontal white matter (FWM), basal ganglia (BG) and corpus callosum (CC), of individuals in all four above-described groups. We used RNAscope and DNAscope ISH to detect vRNA and vDNA, respectively.

HIV vDNA Detected in the Brain Tissues of Aviremic Individuals on Suppressive ART

Fig. 1 Representative image of HIV vDNA+ cells detected in the brain tissues of HIV infected aviremic individuals on suppressive ART. HIV vDNA-positive cells (a discreet red dot in a nucleus, red circle; virally suppressed subject 00009, FWM) were detected using sense probes from the RNAscope® ISH probe-V-HIV1-clade B and RNAscope® 2.5 HD assay-Red as a substrate (Advanced Cell Diagnostics). Cell nuclei were counterstained with hematoxylin.
We first examined HIV-1 DNA in all three brain regions using DNAscope ISH. HIV vDNA signals (red puncta) were consistently detected in all individuals from the three HIV-infected groups including those who were virally suppressed (Fig. 1). We then quantified the frequency of vDNA+ nuclei in the entire section normalized with the total number of hematoxylin-counterstained nuclei. HIV vDNA+ cells were found in all three brain regions. A two-way ANOVA with interaction effect between brain areas and groups was used to compare HIV vDNA+ cell numbers. While the interaction effect between brain areas and groups was significant \( (p = 0.0248) \), we performed a post-hoc analysis using Tukey test. The means of HIV vDNA+ cell numbers were compared between groups within each brain area as depicted in Fig. 2. Virally suppressed subjects with or without HAND had significantly fewer HIV vDNA+ cells in the FWM compared to the subjects with HIVE (Fig. 2a; \( p < 0.0001 \)). However, no statistically significant difference in the number of HIV vDNA+ cells in the BG was found across the groups (Fig. 2b, all \( p \)-values >0.3). Likewise, in CC, virally suppressed subjects with or without HAND had significantly fewer HIV vDNA+ cells compared to the subjects with HIVE (Fig. 2c; \( p = 0.0010 \)).

**Fig. 2** Comparison of vDNA levels between HIV-infected groups by brain area. We compared the distribution of viral DNA (vDNA) in three groups (G2 HIVE, G3 HAND, and G4 No HAND) through a two-way ANOVA with Tukey multiple comparison test. a shows frontal white matter (FWM), b basal ganglia (BG), and c corpus callosum (CC) DNA. HIVE: human immunodeficiency virus encephalitis; HAND: HIV-associated neurocognitive disorders

**Fig. 3** Correlation of Global Deficit Score (GDS) to HIV vDNA in virally suppressed groups G3 and G4. a G3 (HAND) group, and b G4 (No HAND) group. The slopes were not statistically significant except for one slope with CC in G3 (a; \( r = 0.9059, p = 0.0129 \)).
suppressed subjects with HAND had no significant difference in the number of HIV vDNA+ cells compared to the subjects with HIVE, although virally suppressed subjects with no HAND had significantly fewer HIV vDNA+ cells than those with HIVE (Fig. 2c; \( p < 0.001 \)).

While there was no difference in the number of vDNA+ cells between virally suppressed patients with HAND and those without HAND, we sought to investigate the relationship between HIV DNA levels and global deficit score (GDS). When we examined the relationship between the number of vDNA+ cells in specific brain regions and GDS among virally suppressed subjects, we found that there was a strong positive correlation between the number of HIV vDNA+ cells in the CC and GDS among virally suppressed subjects with HAND (Fig. 3; \( r = 0.906, p = 0.0129 \)). This suggests that the presence of HIV-1 DNA in the brain, specific to particular regions including corpus callosum, may be important in inducing neurocognitive impairment.

We next examined HIV vRNA in all three brain regions of all individuals from the three HIV-infected groups, including those who were virally suppressed. Abundant HIV RNA was readily detected in all the brain regions from HIVE group (Supplementary Fig. 1). We can distinguish cell-free vRNA (virion, Fig. S1b, black arrowheads) from cell-associated vRNA using the single-copy sensitive RNAscope ISH. As shown in Fig. S1, vRNA in the brains of HIVE group exists mainly in cell-associated form around small blood vessels. We did not detect any in situ signals in the subjects from negative control group using HIV-1 sense or antisense probes, and we also did not detect any in situ signals from the subjects of HIVE group using negative control probe (data not shown). In the majority of the virally suppressed aviremic subjects, we did not detect vRNA signals. However, we detected small clusters of isolated vRNA signals, which were infrequent and very focal, in 3 of 8 individuals from HAND group (01986, 00006, 00009) and 3 of 8 individuals from No HAND group (00658, 01878, 02087) (Fig. 4). Of note, vRNA signals morphologically appear as discrete red puncta representing cell-free virions (Fig. 4b & d, arrowheads), which differ from vRNA signals in HIVE group where abundant HIV vRNA signals were readily apparent in all the brain regions (Fig. S1) and the entire cytoplasm of the infected cells was filled with strong red puncta making individual puncta impossible to discriminate (Fig. S1b).
Next, we sought to determine the cellular phenotype of vDNA+ cells in the brain, using DNAscope ISH in combination with IHC for CD68 (activated microglia/macrophages), CD206 (PVM) and GFAP (astrocytes). In the brain of virally suppressed subjects, HIV vDNA+ cells were found to be either CD68+ (Fig. 5a) or CD206+ (Fig. 5b), but not GFAP+ (Fig. 6a). Interestingly, many if not all vDNA+ cells are located around the vessels, suggesting, with their CD206 immunoreactivity, that they are PVM (Fabriek et al. 2005; Vogel et al. 2013; Holder et al. 2014). After we individually examined a minimum of 40 vDNA+ cells each from virally suppressed cases, we were not able to find any single vDNA+GFAP+ cells. In HIV, cells harboring vDNA are also exclusively CD68+ microglia/macrophages (data not shown). We also examined the type of cells harboring vRNA in viremic subjects from the HIVE group, vRNA+ cells were exclusively colocalized with CD68 and CD206 (Supplementary Fig. 2a-f, black arrows). We found no evidence of the presence of vRNA in GFAP+ astrocytes in the brain with HIVE (Fig. 6b).

Recently, we demonstrated that a myeloid-specific host restriction factor SAMHD1 protein is upregulated and phosphorylated in the brain during SIV infection and correlates with levels of brain SIV DNA (Lindgren et al. 2018). In the current study, we examined SAMHD1 protein expression in the brain of HIV patients with HIVE and virally suppressed patients with or without HAND. There was a significant positive correlation between the number of SAMHD1+ nuclei and the number of HIV vDNA+ cells in the FWM ($r = 0.5401, p = 0.0096$) and BG ($r = 0.6609, p = 0.0006$) although we found no correlation in the CC (Supplementary Fig. 3).

**Discussion**

Previously, using a simian immunodeficiency virus (SIV)-infected macaque model of HIV infection, Clements and colleagues showed that SIV DNA remained detectable in brain after HAART although viral replication in the brain and CSF...
was suppressed (Zink et al. 2010). A few brain studies examined the presence of HIV DNA by qPCR in the brains of HIV-infected, ART-treated subjects (Gelman et al. 2013; Lamers et al. 2016). However, it remains to be demonstrated which cell type(s) harbors HIV DNA and/or RNA in the brain of HIV patients receiving HAART that suppresses plasma viral load to undetectable levels (“virologically suppressed patients”). The paucity of postmortem brain tissue from those who achieved viral suppression has hindered such investigations. In the present study, we are able show that cells harboring HIV-1 DNA persist in the brain despite suppressive ART and that these cells are exclusively macrophages/microglia. Moreover, we found the presence of low-level HIV-1 RNA in focal brain areas in a minority of virologically suppressed patients, suggesting either spontaneous viral reactivation or ongoing low level replication despite suppressive ART. Notably, the detected vRNA morphologically resembles cell-free virions, which can infect adjacent cells to replenish reservoir. This is the first formal demonstration that HIV-1 RNA can be expressed in brains of virally suppressed patients. Therefore, the present manuscript demonstrates brain macrophages as a potential target for anti-HIV therapy. While our manuscript was under revisions, Tso et al. (2018) also reported that subtype C HIV-1 was detected by droplet digital PCR in the brains of two of four virologically suppressed cases. They also demonstrated colocalization of HIV vDNA with CD68+ macrophages/microglia in one virologically suppressed case by combined DNAscope ISH and IHC (Tso et al. 2018).

Interestingly, we found no evidence of the presence of vDNA or vRNA in GFAP+ astrocytes in the brain of aviremic or viremic HIV-infected patients. The role of astrocytes as an HIV reservoir remains very controversial with a few recent studies demonstrating the association of HIV-1 DNA with astrocytes (as well as neurons, in one study) using laser capture microdissection (LCM) (Trillo-Pazos et al. 2003; Churchill et al. 2009; Thompson et al. 2011). Trillo-Pazos et al. detected the presence of HIV-1 gag DNA in pooled samples of 100 astrocytes from the frontal cortical tissues of a pediatric and an adult AIDS case. Likewise, Thompson et al. detected HIV-1 gag DNA in 11 to 17% and 0 to 23% astrocytes in occipital regions of HIV+ and HIV-1 cases, respectively. However, whether astrocytes are infected remains to be proven as reactive astrocytes serving as phagocytes has been recently suggested. Churchill et al. have shown increased presence of HIV DNA in LCM-isolated astrocytes when subanalyzed in association to proximity to PVM in AIDS cases. Furthermore, a recent study using cultured human fetal astrocytes suggests that HIV-1 DNA in astrocytes occurs by uptake of HIV-1-infected debris by cell-cell interaction with macrophages (Russell et al. 2017). Alternatively, the close spatial proximity of HIV-infected macrophages/microglia may serve as a source of contamination in examination of astrocytes. In the current study, however, we have not identified the presence of HIV-1 DNA or RNA, using single-copy sensitive RNAscope and DNAscope, respectively, in GFAP+ astrocytes in the brain of aviremic or viremic patients, which challenges the findings of HIV-1 DNA in astrocytes seen in these studies. Interestingly, in vitro studies on HIV infection of astrocytes have shown that once a block to HIV fusion and entry is artificially bypassed, there was no post-entry restriction to HIV-1 replication (Canki et al. 2001; Russell et al. 2017). The lack of intracellular restriction evolved in human primary astrocytes indicates no virus-driven selection in this cell type during primate evolution.

When comparing the three HIV groups, we noticed a trend of increased frequency of HIV-1 vDNA+ cells, specifically in the CC, from virally suppressed subjects without HAND, to

![Representative images of HIV-1 vDNA and vRNA not colocalizing with astrocytes in the brain tissues of HIV-infected aviremic individuals on ART and viremic HIV+ subjects respectively.](image)
subjects with HAND, and to subjects with HIVE. The above findings along with the observation of a strong positive correlation between HIV vDNA+ cells in the CC and GDS in virally suppressed subjects with HAND may suggest a potential role of HIV in the brain in the development of neurocognitive impairments despite suppressive long-term HAART. Brain imaging studies of HAART treated HIV patients have previously shown selective white matter disease (Garvey et al. 2014; Ragin et al. 2015; Randall et al. 2017; Buyukturkoglu et al. 2018) and a correlation between loss of CC integrity with neurocognitive deficits (Wu et al. 2006; Kelly et al. 2014). However, it is still unclear whether the neurocognitive impairment in the era of HAART is due to ART neurotoxicity or HIV induced neuroinflammatory responses.

In summary, this study has identified for the first time the persistence of HIV vDNA+ cells in the brain of virally suppressed patients. Using DNAscope in situ hybridization technique, we found that HIV-1 DNA is harbored exclusively in brain macrophages/microglia, especially PVM, but not astrocytes. Importantly, in a minority of virally suppressed aviremic patients, isolated and focal vRNA was detected, indicating there was a spontaneous viral reactivation and/or an ongoing low-level focal replication despite suppressive ART. Taken together, our findings suggest that brain macrophages are a important HIV reservoir.

Acknowledgements This study was supported by an NIH Grant R01MH107333 and its supplement (to W.-K.K.), as well as by the following NIH Grants through the NIMH and NINDS: U24MH100931 (Manhattan HIV Brain Bank); U24MH100930 (Texas NeuroAIDS Research Center); U24MH100929 (National Neurological AIDS Bank); U24MH100928 (California NeuroAIDS Tissue Network); U24MH100925 (Data Coordinating Center). The authors thank Ms. Elizabeth Kulkka at NNCT Data Coordinating Center for her assistance with the dataset used in this study. The authors thank Dr. Susan Morgello at Manhattan HIV Brain Bank for her review of the manuscript and assistance with slide orientation.

Compliance with Ethical Standards

Conflict of Interest The authors declare no competing financial interests. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of the NNCT or NIH.

Ethical Approvals This article does not contain any studies with human participants performed by any of the authors. A Not Human Subjects Research determination was made by the Eastern Virginia Medical School Institutional Review Board. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. For the detailed ethical statement, please refer to materials and methods.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherter M, Clifford DB, Cingue P, Epstein LG, Goodkin K, Gislen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sackett N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799

Baeuerle M, Schmitt-Haende M, Taubald A, Mueller S, Walter H, Pfeiffer C, Manger B, Harrer T (2005) Severe HIV-1 encephalitis and development of cerebral non-Hodgkin lymphoma in a patient with persistent strong HIV-1 replication in the brain despite potent HAART – case report and review of the literature. Eur J Med Res 10:309–316

Becker JT, Sanders J, Madsen SK, Ragin A, Kingsley L, Maruca V, Cohen B, Goodkin K, Martin E, Miller EN, Sackett N, Alger JR, Barker PB, Saharan P, Carmichael OT, Thompson PM, Multicenter AIDS Clinical Studies (1995) Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav 5:77–85

Bingham R, Ahmed N, Rangi P, Johnson M, Tyer M, Green J (2011) HIV encephalitis despite suppressed viremia: a case of compartmentalized viral escape. Int J STD AIDS 22:608–609

Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Ellis RJ, Atkinson JH, Grant I, Heaton RK (2012) Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 26:894–908

Buyukturkoglu K, Fleyser L, Byrd D, Morgello S, Inglese M (2018) Diffusion kurtosis imaging shows similar cerebral axonal damage in patients with HIV infection and multiple sclerosis. J Neuroimaging 28:320–327

Canki M, Thai JN, Chao W, Ghoparde A, Potash MJ, Volsky DJ (2001) Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes. J Virol 75:7925–7933

Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, Gorry PR (2009) Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 66:253–258

Cysique LA, Brew BJ (2011) Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neuro-Oncol 107:176–183

Fabriek BO, Van Haastert ES, Galea I, Polliet MM, Dopp ED, Van Den Heuvel MM, van den Berg TK, De Groot C, van d, Dijkstra CD (2005) CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 51:297–305

Fischer-Smith T, Croul S, Vernikos AE, Capini C, L’Heureux D, Regulier EG, Richardson MW, Amini S, Morgello S, Khalili K, Rappaport J (2001) CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neuro-Oncol 7:528–541

Garvey LJ, Pavese N, Politis M, Ramlakshansingh A, Brooks DJ, Taylor-Robinson SD, Winston A (2014) Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS 28:67–72

Gelman BB, Lisnicichia JC, Morgello S, Masliah E, Commins D, Achim CL, Fox HS, Kolson DL, Grant I, Singer E, Yiannoutsos CT, Sherman S, Gensler G, Moore DJ, Chen T, Soukup VM (2013) Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr 62:487–495

Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B (2011)
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25:625–633

Holder GE, McGary CM, Johnson EM, Zheng R, John VT, Sugimoto C, Kuroda MJ, Kim WK (2014) Expression of the mannose receptor CD206 in HIV and SIV encephalitis: a phenotypic switch of brain perivascular macrophages with virus infection. J Neuroimmune Pharmacol 9:716–726

Janssen RS, Cornblath DR, Epstein LG, Foa RP, Sidtis JJ (1991) Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a working group of the American academy of neurology aids task force. Neurology 41:778–785

Kelly SG, Taiwo BO, Wu Y, Bhatia R, Kettering CS, Gao Y, Li S, Hutten R, Ragin AB (2014) Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum. J Neuro-Oncol 20:514–520

Lamers SL, Rose R, Maidji E, Agsalda-Garcia M, Nolan DJ, Fogel GB, Salemi M, Garcia DL, Bracci P, Yong W, Commis D, Saïd J, Khanlou N, Hinkin CH, Sueiras MV, Mathissen G, Donovan S, Shiramizu B, Stoddart CA, McGrath MS, Singer EJ (2016) HIV DNA is frequently present within pathologic tissues evaluated at autopsy from combined antiretroviral therapy-treated patients with undetectable viral loads. J Virol 90:8968–8983

Li Q, Skinner PJ, Duan L, Haase AT (2009) A technique to simultaneously visualize virus-specific CD8+ T cells and virus-infected cells in situ. J Vis Exp (30):e1561. https://doi.org/10.3791/1561

Lindgren AA, Filipowicz AR, Hatler JB, Kim SO, Chung HK, Kuroda MJ, Johnson EM, Kim WK (2018) Lentiviral infection of proliferating brain macrophages in HIV and simian immunodeficiency virus encephalitis despite sterile alpha motif and histidine-aspartate domain-containing protein 1 expression. AIDS 32:965–974

Masliah E, DeTeresa RM, Mallory ME, Hansen LA (2000) Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14:69–74

McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N (2003) Human immunodeficiency virus-associated dementia: an evolving disease. J Neuro-Oncol 9:205–221

Ragin AB, Wu Y, Gao Y, Keating S, Du H, Sammet C, Kettering CS, Epstein LG (2015) Brain alterations within the first 100 days of HIV infection. Ann Clin Transl Neurol 2:12–21

Randall SR, Warton CMR, Holmes MJ, Cotton MF, Laughton B, van der Kouwe AJW, Meintjes EM (2017) Larger subcortical gray matter structures and smaller corpora Callosa at age 5 years in HIV infected children on early ART. Front Neuroanat 11:95

Russell RA, Chojnicki J, Jones DM, Johnson E, Do T, Eggeлин G, Padilla-Parras S, Sattentau QJ (2017) Astrocytes resist HIV-1 fusion but engulf infected macrophage material. Cell Rep 18:1473–1483

Sacktor N, McDermott MP, Marder K, Schiffito G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neuro-Oncol 8:136–142

Simioni S, Cavassini M, Annoni JM, Rimbault AA, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250

Thompson KA, Cherry CL, Bell JE, McLean CA (2011) Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am J Pathol 179:1623–1629

Trillo-Pazos G, Diamanturos A, Rislove L, Menza T, Chao W, Belem P, Sadiq S, Morgello S, Sharer L, Volsky DJ (2003) Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol 13:144–154

Tso FY, Kang G, Kwon EH, Julius P, Li Q, West JT, Wood C (2018) Brain is a potential sanctuary for subtype C HIV-1 irrespective of ART treatment outcome. PLoS One 13:e0201325

Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van d'V, Amor S, Teunissen CE, van Horssen J, Dijkstra CD (2013) Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 10:35

Wang LX, Kang G, Kumar P, Lu W, Li Y, Zhou Y, Li Q, Wood C (2014) Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection. Proc Natl Acad Sci U S A 111:3146–3151

Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, Hinkin CH, Lazzaretto D, Chermer N, Marcotte TD, Gelman BB, Morgello S, Singer EJ, Grant I, Heaton RK (2004) Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 26:759–778

Wu Y, Storey P, Cohen BA, Epstein LG, Edelman RR, Ragin AB (2006) Diffusion alterations in corpus callosum of patients with HIV. AJNR Am J Neuroradiol 27:656–660

Yuan Z, Wang N, Kang G, Niu W, Li Q, Guo J (2017) Controlling multicyle replication of live-attenuated HIV-1 using an unnatural genetic switch. ACS Synth Biol 6:721–731

Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, Adams RJ, Bartizal C, Varrone J, Rabi SA, Graham DR, Tarwater PM, Mankowski JL, Clements JE (2010) Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 202:161–170